Interleukin and ABGI sign research deal

Massachusetts, USA-based personalized health company Interleukin Genetics has established a new research agreement with Access Business Group International, a subsidiary of Alticor. The four areas covered by the accord are: osteoporosis; cardiovascular disease; nutrigenomics; and dermagenomics.

Under the terms of the deal, Interleukin, which will receive approximately $1.2 million in funding this year and will attempt to correlate single nucleotide polymorphism data with the risk of developing osteoporosis or CV disease in Asian populations. The firm will also carry out studies to try to identify genetic risk factors that influence athletic performance and skin appearance, for use in subsequent product development work.

The agreement, the eighth the firms have established in recent years, will also see Interleukin receive an additional $800,000 in funding that was not spent during previous projects. Further details of the partnership were not disclosed.